<DOC>
	<DOC>NCT00141453</DOC>
	<brief_summary>The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.</brief_summary>
	<brief_title>ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes albumintocreatinine ratio &gt;= 300 mg/g creatinine in first morning urinalysis serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men type 1 diabetes nondiabetic nephropathy history of myocardial infarction history of cardiac bypass grafting within 3 months history of percutaneous coronary intervention (PCI) within 6 months history of carotid artery or peripheral artery revascularization within 6 months stroke or transient ischemic attack (TIA) within 1 year unstable angina pectoris heart failure of NYHA functional classes III or IV rapid progression of kidney disease within 3 months severe orthostatic hypotension serum potassium level =&lt;3.5 mEq(mmol)/L or =&gt;5.5 mEq(mmol)L history of rapid elevation of the serum creatinine level after starting treatment with AII receptor antagonists or ACE inhibitors poor glycemic control: HbA1c level =&gt;11% history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>angiotensin II type I receptor blockers</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>renal failure</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>olmesartan medoxomil</keyword>
</DOC>